Biotechnology

BMY Breaking New Ground in Schizophrenia Treatment

Bristol Myers Squibb's Cobenfy, the first new schizophrenia treatment in over 70 years, offers hope for patients and investment potential for the market.

Viridian Therapeutics: A Biotech Tapping High-Growth Potential

See how Viridian Therapeutics (NASDAQ: VRDN) is innovating thyroid eye disease treatments with advanced therapies and a growing market opportunity.

Billion-Dollar Market Potential for Targeted Cancer Therapies

Radiopharmaceuticals are revolutionizing cancer treatment, attracting billions in investments. Discover the potential and challenges for investors in this emerging market.

Roche Shares Tumble After Obesity Drug Data

Roche's stock dropped 4.5% due to gastrointestinal side effects from its obesity drug CT-388, raising concerns among investors about the drug's future.

Integra LifeSciences Implements Quality Compliance Plan

Integra LifeSciences' commitment to quality compliance and supply chain resilience may yield growth opportunities for retail investors' portfolios.

Viking Therapeutics Accelerates Weight Loss Drug Development

Viking Therapeutics' fast-tracked weight loss injection could reshape the market, impacting investors' portfolios and strategies.

Biogen Tops Q1 Estimates with Alzheimer's Boost

Dive into Biogen's impressive Q1 earnings, featuring an EPS beat and significant LEQEMBI sales growth. Explore what these results mean for the company's 2024 outlook.

Contineum Therapeutics Raises $110 Million in Successful IPO

Contineum Therapeutics' IPO success reflects investor confidence in their innovative therapies for neuroscience, inflammation, and immunology.

Johnson & Johnson (JNJ) Acquires Shockwave Medical (SWAV) for $13.1B

J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the cardiovascular technology sector.

Carl Icahn Ends Second Proxy Fight with Illumina (ILMN) Board

Activist investor Carl Icahn spares Illumina a second proxy contest, but continues lawsuit, leaving retail investors curious about board dynamics and legal implications.

Biopharmaceutical M&A Surge Revitalizes Industry

Uncover the latest M&A trends in biopharma, featuring big moves by BMY, MRK, BSX, and JNJ in a market ripe with opportunity.

Eli Lilly's Zepbound Shows Short-Lived Weight Loss Benefits

Uncover key investment insights in the dynamic obesity drug market. Discover growth, value, and momentum strategies in this evolving healthcare sector.

AbbVie Stock in Focus with Strategic Cerevel Acquisition

AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.

Gilead Sciences Marks Two Years of Robust Growth

Gilead Sciences reports robust Q3 growth, driven by oncology and HIV treatments, highlighting a solid pipeline and strategic expansion in global markets. The company is poised for a busy 2024 with multiple clinical updates.

Exact Sciences Records Stellar Q3 2023 Results

Exact Sciences showcases robust Q3 results, marking a turning point with increased revenue, diversified streams, and an upward trajectory.